Lysosomes can trigger the mitochondrial apoptotic pathway by releasing proteases. Here, we report that a 25-kDa protein purified from rat liver lysosomes possesses a long-standing potent Bid cleavage activity at neutral pH, and the truncated Bid could in turn induce rapid mitochondrial release of cytochrome c. This protease was revealed as chymotrypsin B by biochemical and mass spectrometric analysis. Although it was long recognized as a digestive protease exclusively secreted by the exocrine pancreas, our data support that it also expresses and intracellularly resides in rat liver lysosomes. Translocation of lysosomal chymotrypsin B into cytosol was triggered by apoptotic stimuli, such as TNF-α; and intracellular delivery of chymotrypsin B protein induced apoptotic cell death with a potency comparable to cathepsin B, suggestive of a lysosomal-mitochondrial pathway to apoptosis regulated by chymotrypsin B following its release. Noteworthily, either knockdown of chymotrypsin B expression by RNAi or pretreatment with chymotrypsin B inhibitor N-p-tosyl-L-phenylalanine chloromethyl ketone significantly reduced TNF-α-induce apoptosis. These results demonstrate for the first time that chymotrypsin B is not only restricted to the pancreas, but can function intracellularly as a pro-apoptotic protease.
Introduction
Apoptosis is an evolutionarily conserved process critical in various biological events, such as embryonic development, maintenance of tissue homeostasis, and removal of damaged cells. Mitochondria are viewed as one of the most pivotal sensors and amplifiers in an apoptotic process by releasing apoptogenic proteins such as cytochrome c, Smac/DIABLO, and endonuclease G following mitochondrial membrane permeabilization (MMP) [1] . MMP is mainly mediated by Bcl-2 protein family members [2] . Bid (BH3 interacting domain death agonist) is an abundant proapoptotic member of the Bcl-2 family, which following activation through proteolytic cleavage, is involved in various pathways of apoptosis that interplay the activation of caspases with mitochondria dysfunction [3, 4] . Recently accumulating evidence has indicated that, in addition to mitochondria, lysosomes also play important roles in the apoptosis [5] . As reported, several lysosomal acid-dependent proteases, known as cathepsins, have been implicated in apoptosis induction following their relocalization to the cytosol as a result of moderate lysosomal rupture, probably via activation of the mitochondrial apoptotic pathway [6] [7] [8] . Interestingly, proteolytic activation of Bid may present a mechanism through which extra-lysosomal cathepsins can elicit MMP and subsequent caspase activation. Many isoforms of cathepsins (cathepsins B, H, L, S, K, X, C and D) have been identified to be Bid-cleaving proteases. Incubation of full-length Bid with cathepsins B, H, L and S, respectively, resulted in Bid activation and subsequent rapid cytochrome c release from isolated mitochondria. The physiological functions of cathepsins, however, have been controversial because they are usually autolyzed or denatured in the physiological conditions of the cytosol [9] . In the course of our study of mitochondrial membrane permeabilization [10, 11] , an unknown caspase 8-like activity capable of converting Bid into truncated Bid (tBid) at neutral pH was detected in highly purified rat liver lysosomal extracts. This gave us an impetus to purify the responsible lysosomal protease(s). In the present study, we report the purification and characterization of one of the proteases termed Lysosomal Bid Cleavage Protease (LBCP). The cleavage site on Bid by LBCP is different from that of caspase 8, lysosomal cathepsins, granzyme B and calpain. By mass spectrometric assays, analysis of inhibitor specificity, and a determination of its Bid cleavage sites, LBCP was found to be identical to chymotrypsin B, a robust and stable serine endopeptidase previously known as an intestinal digestive enzyme expressed and secreted solely by the exocrine pancreas. Upon stimulation with TNF-α, the intralysosomal chymotrypsin B was released into the cytosol, triggered the release of mitochondrial cytochrome c, and resulted in apoptosis through activation of the mitochondrial apoptotic pathway.
Methods

Expression and purification of recombinant proteins
Mouse Bid expression plasmid constructed in pET-23d vector was kindly provided by Dr. Bruno Antonsson (Serono Pharmaceutical Research Institute, Switzerland). The Bid protein was expressed and purified as described previously [10] . Expression and purification of cystatins A and B in pHD389 vector, kindly provided by Dr. Ingemar Björk (Swedish University of Agricultural Sciences, Sweden), essentially followed his method. The SERPINB3 and SERPINB4 expression constructs (the coding sequences inserted into the pGEX-2T vector) were obtained from Dr. Gary A. Silverman (Harvard Medical School, USA). The recombinant proteins glutathione-S-transferase (GST) -SERPINB3 and -SERPINB4 were batch purified using glutathione-Sepharose columns (Amersham). The c-IAP-1 expression plasmid constructed in pGEX4T was a gift from Dr.
Xiaodong Wang (University of Texas Southwestern Medical Center, USA). The GST-c-IAP-1 fusion protein was affinity purified on glutathione-Sepharose by standard methods. The rat chymotrypsinogen B expression vector constructed in pET-17b was a generous gift from Dr. László Gráf (Eötvös Loránd University, Hungary). The vector was transformed into the BL21 (DE3) pLysS Escherichia coli strain. After induction with IPTG for 3 hr, the cells were collected in a 1/10 volume of 0.1 M Tris-HCl, pH 8.0, 10 mM EDTA and frozen. The cells were then thawed and sonicated, and the inclusion body fraction was pelleted at 12,000×g for 30 min. The pellet was resuspended in ~30 ml Triton wash solution (0.5% Triton X-100, 50 mM Tris-HCl, pH 8.0, 0.1 M NaCl) using a homogenizer. The inclusion bodies were pelleted at 25,000×g for 10 min. This wash was repeated 4 times and one final wash was performed to remove any remaining Triton using the homogenizer again in 50 mM Tris-HCl, pH 8.0, 0.1 M NaCl. For renaturation of the expressed protein, the inclusion body fraction was solubilized with 6 M GuHCl, 0.1 M Tris-HCl, pH 8.0, 100 mM DTT. The solubilized protein was dialyzed against the refolding buffer containing 5 mM cysteine, 1 mM cystine, 50 mM Tris-HCl pH 8.0, 5 mM EDTA, and GuHCl with its concentration continually decreasing from 3 M to 1 M. The renaturation process was conducted at 4 °C for 24 hr. The renatured protein solution was then dialyzed against 2 mM HCl, 10 mM CaCl 2 and ultracentrifuged (78,100×g, 30 min). The zymogen was activated by trypsin (Sigma) at a 200:1 (w/w) zymogen/trypsin ratio. After treatment with L-1-chloro-3-[4-tosylamido]-7-amino-2-heptano ne (TLCK; ICN), the active form was purified by affinity chromatography on an SBTI-Sepharose column (Sigma). Immediately after chymotrypsin B was eluted from the column with 1 mM HCl, the solution was neutralized with ammonia, and then lyophilized. The purity of the preparation was analyzed by SDS-PAGE. The enzyme concentration was determined by active site titration with 4-methylumbelliferyl p-trimethylammoniocinnamate chloride (MUTMAC, Sigma). Preparation of lysosomes and mitochondria Lysosomes were purified from the livers of Sprague-Dawley rats according to the method described by Stoka et al. [6] with modifications. We analyzed all purifications with one lysosomal and two mitochondrial markers to minimize any cross-contamination between the two organelles. To eliminate the contamination of mitochondria, the lysosomal fractions were incubated for 3 min at 37 o C in the presence of CaCl 2 (final concentration 1 mM). Soluble lysosomal constituents were released by three freeze-thaw cycles with a 15-s vortex between each cycle. The suspension was centrifuged at 10,000 ×g for 10 min to pellet the lysosomal membranes, and the supernatant was collected. Mitochondria were isolated from Sprague-Dawley rat livers according to the protocol described by Luo et al. [3] . Purification of lysosomal Bid cleavage protease Five batches of lysosomal extracts from 20 rat livers were used as the starting material for the following purification procedures until the last step. All steps were carried at 4 o C unless otherwise noted. The Bid cleavage activity at pH 7.6 was followed after each step (Zhai et al., 2001 ). After dialysis against buffer A (25 mM Tris-HCl at pH 7.6, 10 mM NaCl, 10 mM 2-mercaptoethanol) containing 0.5 M NaCl, the lysosomal extract was loaded onto a 3-ml lentil lectin column (Amersham) and was re-circulated to provide sufficient interaction with the medium. The flow-through from the affinity column was then dialyzed against buffer A, followed by acidification at a final concentration of 200 mM NaAc/HAc at pH 5.0. Following incubation for 2 hr at 37 o C and centrifugation for 10 min at 15,000×g, the supernatants were collected and dialyzed against buffer A. This solution was then loaded onto a Bio-Scale Q5 column (Bio-Rad) equilibrated with buffer A, and eluted with a linear gradient of 45 ml from buffer A to buffer A containing 600 mM NaCl. Active fractions were pooled and, at a final concentration of 1.0 M ammonium sulfate, loaded onto a MP7 HIC column (50 × 7.8 mm, Bio-Rad) equilibrated with 1.0 M ammonium sulfate in buffer A. 10 ml of buffer A containing 200 mM ammonium sulfate was applied to the column, and the eluate collected and dialyzed against 25 mM ammonium formate at pH 7.4 containing 5 mM NaCl. The solution was lyophilized, re-dissolved in 0.5 ml of buffer A containing 150 mM NaCl, and loaded onto a Superdex 200 10/30 column coupled with a Superdex 75 10/30 column (Amersham), equilibrated, and eluted with buffer A containing 150 mM NaCl. The active fractions were stored at 4 o C till all five batches were processed to this point. At the last step, all batches of the active fractions from the gel-filtration columns were pooled. After dilution to lower the concentration of NaCl to 100 mM, the solution was loaded onto a Mono Q 5/5 column (Amersham) equilibrated with buffer A containing 100 mM NaCl, and eluted with 30 ml of buffer A containing a linear gradient of NaCl increasing from 100 mM to 600 mM. Fractions of 0.4 ml were collected and assayed for Bid cleavage activity.
In-gel digestion and mass spectrometric identification 0.4 ml of the active peak fraction from the last purification step was lyophilized, re-dissolved in 5 120 µl of 1×SDS-PAGE loading buffer, and subjected to 15% SDS-PAGE. After staining with colloidal blue (Invitrogen), the ~25K bands that corresponded with the activity were subjected to in-gel digestion with trypsin (10 ng/µl). The tryptic peptides were extracted and dried in a vacuum centrifuge, and were analyzed by LC-MS/MS using a nano-scale C18 column coupled in-line with an ion trap mass spectrometer (LCQ Deca, Thermo Finnigan).
The instrument was run in data-dependent mode, cycling between one full MS scan and MS/MS scans of the three most abundant ions. The MS and MS/MS data were used to search the non-redundant NCBI protein database using MASCOT software.
Effect of inhibitors on the Bid cleavage activity
Aliquots from the Mono Q fraction at the peak of Bid cleavage activity were preincubated for 30 min at 37 o C in the presence of 0.1 mg/ml aprotinin (inhibitors were from Sigma unless otherwise indicated), 5 mM benzamidine, 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mg/ml soybean trypsin inhibitor (SB-TI), 0.25 mM chymostatin, 5 mM N-ethylmaleimide, 20 µM E-64, 0.2 mM 3,4-dichloroisocoumarin
chloromethyl ketone (TPCK), 5 mM iodoacetamide, 10 µM pepstatin A, 10 mM EDTA, 10 mM ortho-phenanthroline, 1 µM caspase-1 inhibitor I (Ac-YVAD-CHO; Calbiochem), 100 µM caspase-3 inhibitor I (Ac-DEVD-CHO), 1 µM caspase-8 inhibitor I (Ac-IETD-CHO), 0.25 mM cathepsin inhibitor I (Z-FG-NHO-Bz), SERPINB3 (500:1, molar ratio), SERPINB4 (500:1), cystatin A (500:1), cystatin B (500:1), or c-IAP1 (500:1). 10 µg of Bid was then introduced into each incubation mixture, and the final volume adjusted to 20 µl. With the rat chymotrypsinogen B expression vector pET-17b lacking 51 nucleotides encoding N-terminal signal peptide of the chymotrypsinogen B precursor, the coding sequence was amplified using the following two primers: 5′-TTTAAGCTTATGGCATTCCTTTGGCTC GTGTCCTGCTTTGCCCTTGTGGGGGCCAC CTTTGGCTGTGGAGTCCCTACCATCC-3′ (sense), and 5′-AAAGGATCCTCAGTTGGCTTCCAAGAT CTG-3′ (anti-sense). The PCR product and pEGFP-N1 (Clontech) were cut with Hind III and BamH I (TaKaRa), followed by purification and ligation. Transformed competent cells (TianWei, China) were plated on selective agar plates, and colonies were selected and grown up in LB media containing 50 µg/ml kanamycin. The sequences were verified by DNA sequencing. In order to check whether the new construct generate functional proteins, the proteins were expressed in vitro using the Promega TNT coupled transcription-translation system (Promega) and radiolabeled with [
35 S]-methionine (Amersham). Efficiency of expression was monitored by analyzing the translation with SDS-PAGE and autoradiography. Expression plasmids for transfection were purified using the Plasmid Midi kit (Qiagen). The expression plasmids were transfected into RH-35 cells using Lipofectamine Plus reagent (Invitrogen) according to the procedure recommended by the manufacturer. The expression vector for LAMP-2-CFP was a generous gift from Dr. GJ Gores (Mayo Medical School, USA). In brief, RH-35 cells grown in 35 mm dishes at 60 % confluence were transfected with 4 µg of the plasmid, 6 µl of lipid, and 6 µl of Plus reagent in 0.8 ml of DMEM without antibiotics. To obtain stable transfected cell lines, the cells were cultured in DMEM containing 600 µg/ml G418 for 3 weeks.
Delivery of Ctrb into rat RH-35 hepatoma cells
Recombinant chymotrypsin B was delivered to RH-35 rat hepatoma cells by using the BioPORTER  protein transfection reagent (Gene Therapy Systems, USA) according to the manufacturer's instructions. Briefly, 50 µl of Ctrb solution (1 µM) was incubated in the presence or absence of 0.2 mM TPCK for 30 min at 37 o C. Ctrb solutions or PBS (Blank) were then used to hydrate the dried BioPORTER. The solution was pipetted up and down, and incubated at room temperature for 5 min. Finally, the volume of the complexes was brought to 0.5 ml with serum free medium and then transferred directly onto the RH-35 cells.
After incubation for 5 hr, 2 ml of serum-containing medium was added. The cells were incubated overnight and then subjected to apoptosis assays.
RNAi studies
The mammalian expression vector, pSUPER.retro.neo (OligoEngine) was used for expression of siRNA in RH-35 cells. The gene-specific insert specifies a 19-nucleotide sequence corresponding to nucleotides 421-439 of Ctrb. These sequences were inserted into the pSUPER.retro.neo backbone after digestion with BglII and HindIII. This vector was referred to as pSUPER-Ctrb. Considering bioinformatics studies revealed that the empty pSUPER.retro.neo vector might form hairpin oligonucleotide(s) that could interfere the stability of Ctrb mRNA and consequently induce non-specific downregulation of Ctrb, a control vector (pSUPER-LacZ) with no significant homology to Ctrb gene was serves as a non-silencing control. The transient transfections of the RH-35 rat hepatoma cells with pSUPER-Ctrb or pSUPER-LacZ (control) vectors were done with Nucleofector Solution V coupled with program T-030 (Amaxa). Transfected cells were analyzed by real-time PCR for actin and Ctrb using the Bio-Rad MyIQ. Data were calculated by the relative quantitation method, compared to actin as internal control. To determine the effect of RNAi-mediated downregulation of Ctrb on TNF-α-induced apoptosis, transiently transfected RH-35 cells were treated with 100 ng/ml TNF-α for 6 h and subjected to flow cytometry analysis of apoptosis.
Apoptosis assays
Cells were harvested by mild trypsinization, washed with cold PBS, and fixed with 70% ethenol. Cells were stained with propidium iodide and the percentage of hypodiploid (apoptotic) cells with a FACSCalibur flow cytometer and Cell Quest software (Becton Dickinson).
Results
Purification of lysosomal Bid cleavage protease (LBCP)
The impetus for the current study was our previous observation of an unknown caspase 8-like lysosomal protease capable of converting Bid into truncated Bid (tBid) at neutral pH. We took painstaking effort to purify this protease. Fig. 1a shows the many steps involved in purification as we followed the Bid-cleavage activity at pH 7.6. Starting with highly purified lysosome preparations (mitochondrial contaminations lower than 1%) from rat livers, a robust and stable Bid cleavage activity with maximum activity at pH 7.6 was detected in the supernatant (Fig. 1b) after incubation of the lentil lectin flowthrough fraction at pH 5.0 (intralysosomal pH) and 37 o C. This enzymatic activity was designated as lysosomal Bid cleavage protease (LBCP). We believe that it is the incubation that leads to the activation of the LBCP from its premature LBCP zymogen, although the reason is so far not understood. Next, the pH of the active supernatant was changed to 7.0 by dialysis and subjected to anion exchange. As shown in Fig. 1b and 1c, the eluate fractions (fractions 26~32) at ~270mM NaCl ( Fig. 1c) showed the apparent Bid cleavage activity at pH7.6, and corresponded with the appearance of a ~25kDa protein observed on silver stained SDS-PAGE gels (Fig.  1d ). This band was excised and subjected to LC-MS/MS analysis (see "Mass spectrometric identification of LBCP"). To the end, it was estimated that 2 -6 µg of the protein (ca. 0.3 -1 ng/µl) from liver lysosomes of 100 rats could be obtained. The purified LBCP shows a potent Bid cleavage activity since a 10,000 fold molar ratio excess of Bid could be cleaved by LBCP within minutes.
LBCP is identified as chymotrypsin B 1. Biochemical characterization of LBCP
To biochemically characterize the LBCP, a wide range of peptidase inhibitors were assayed for their possible potential on the Bid cleavage activity of the purified LBCP (refer to http://merops.sanger.ac.uk). It can be seen that the proteolytic cleavage of Bid was abolished by PMSF, DCI, SB-TI and chymostatin, but not by inhibitors of other classes ( Fig. 2a and Table 1 ). Noticeably, in contrast to benzamidine and TLCK, TPCK, which belongs to the class of chymotrypsin-like peptidase inhibitors, specifically inhibited the activity of LBCP.
Of five endogenous protein inhibitors tested, only SERPINB3 and SERPINB4 counteracted LBCP to some extent, while cystatins A and B, and c-IAP-1 had no effect. Thus, the inhibition profile suggested that LBCP is a chymotrypsin-like serine protease. To identify Bid cleavage sites by the LBCP, the ~14 kDa C-terminal part of Bid resolved by SDS-PAGE (Fig.2b) was analyzed by electroblotting and N-terminal sequencing, which revealed that the cleavage occurred at Phe67. This site is unique to the action of LBCP (Fig.  2c) . In order to verify this result, a Bid mutant F67A was constructed and processed as described above. As shown in Fig. 2d , the mutant Bid was degraded at a slower rate and a ~17 kDa cleavage product of Bid (F67A) with the N-terminal sequence WEADLE appeared instead of the normal ~14 kDa fragment. The ~17kDa part was identified to be cleaved at Tyr47. The specific cleavage site of Bid by the LBCP supports the idea that this enzyme is a chymotrypsin-like protease. We also used the fluorogenic substrate Suc-AAPF-AMC for a continuous fluorometric assay of LBCP activity. Cleavage of Suc-AAPF-AMC by LBCP showed Michaelis-Menton kinetics with a Km value of 23.7 ± 2.6 µM (Fig. 2e) . This value is shared by rat chymotrypsin B (Ctrb) [12] . Since proteolytic activation of Bid acutely enhances its pro-apoptotic potential [3, 4] , we tested whether LBCP was capable of facilitating the release of cytochrome c from isolated mitochondria through truncation of Bid. As shown in Fig.2f , the apparent release of cytochrome c from mitochondria was observed in the presence of Bid and LBCP.
Mass spectrometric identification of LBCP
The band of LBCP resolved by SDS-PAGE (Fig.1b) was subjected to trypsin digestion and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis (see Supplementary Information, Fig. S1 ). All the tryptic peptides showed 100% identity with the reported sequence of a 28 kDa protein, chymotrypsinogen B (Rattus norvegicus, GI: 6978717). The consistency between these data and the biochemical characterization of LBCP justifies its identification as chymotrypsin B (Ctrb). Expression of chymotrypsin B mRNA and protein in hepatocytes Ctrb, encoded by a single copy nuclear gene [13] (Locus ID: 24291), has been well known as a protease expressed and secreted by the exocrine pancreas. No other tissues had been demonstrated experimentally to contain this enzyme. However, our above results indicated that this enzyme should reside in rat liver. To address this question, we isolated total RNA from both primary rat hepatocytes and RH-35 rat hepatoma cells, and performed reverse transcription (RT)-PCR assay (Fig. 3a) . The sequence of the PCR product was 100% identical to the cDNA sequence of rat Ctrb, supporting the expression of Ctrb in rat liver cells. Furthermore, Western blot analysis of Ctrb protein revealed the existence of Ctrb protein in RH-35 hepatoma cells (Fig. 3b) . Also, a bioinformatics study performed by searching against the gene expression databases UniGene, GeneNote, and GeneCard for the human, mouse, and rat genomes (for details, refer to http://www.ncbi.nlm.nih.gov/UniGene and http://bioinfo.weizmann.ac.il) also implied that Ctrb expression may not be restricted to the pancreas. Lysosomal localization and release of chymotrypsin B Unfavorable against the current concept that, like other members of the chymotrypsin family, Ctrb is a secretory protein, we obtained Ctrb protein from rat liver lysosomes. To verify that Ctrb is indeed localized to liver lysosomes, the intracellular Ctrb was visualized and identified by immunofluorescence. Cathepsin D, a typical lysosomal protease, was used as a marker of lysosomes. RH-35 rat hepatoma cells were fixed, permeablized, incubated with anti-chymotrypsin B antiserum or anti-cathepsin D antibody, respectively, and labeled with proper fluorescent-labeled secondary antibodies. The merged red fluorescence of Ctrb and green fluorescence of Cathepin D (Fig. 4a) verified their colocalization to the same vesicular compartment. To further investigate the intralysosomal localization of Ctrb, Ctrb in its full form pre-chymotrypsinogen B (chymotrypsinogen B precursor containing the N-terminal signal peptide) was tagged with GFP, followed by intracellular delivery of this construct together with another fluorescent reporter plasmid encoding lysosome-associated membrane protein-2-CFP (LAMP-2-CFP), to the RH-35 cells. Both Ctrb-GFP and LAMP-2-CFP displayed a punctuate appearance when viewed by confocal microscopy, indicative of a vesicular compartmentation of the tagged proteins. Overlay images demonstrated virtually complete colocalization of the two fluorescent proteins (Fig.  4b) . Moreover, Ctrb-GFP-transfected cells were co-loaded with LysoTracker Red. The merged red fluorescence of LysoTracker Red and green fluorescence of Ctrb-GFP further verified their colocalization to the same vesicular compartment. Thus, these observations suggest Ctrb is targeted to lysosomes in the RH-35 cells. Since a functional localization of Ctrb in cytosol is a prerequisite to inducing apoptosis, we next studied the release of Ctrb from lysosomes under apoptotic stimuli. RH-35 cells were treated with TNF-α (100 ng/ml). As shown in Fig. 5a , the Ctrb (red fluorescence) underwent redistribution from the vesicular compartments to the cytoplasm in a time-dependent manner, with an onset as early as 2 h after TNF-α administration. Moreover, it is interesting to observe that mitochondrial release of cytochrome c occurred after 8 hrs of TNF-α treatment, later than the lysosomal release of Ctrb (Fig. 5b) .
Verification of involvement of chymotrypsin B in the apoptotic induction
To verify further the cyotosolic Ctrb could induce apoptosis, Ctrb protein was delivered intracellularly to RH-35 cells by BioPORTER. After its administration, we observed a significant release of mitochondrial cytochrome c (Fig. 6a) , chromatin condensation and nuclear fragmentation (Fig.6b) . Moreover, the delivered Ctrb augmented the apoptosis rate to 3.9 times that by the reagent control (Fig. 6c) , comparable to that induced by granzyme B [14] or cathepsin B (data not shown). Neither the TPCK-treated Ctrb nor the delivery reagent alone produced marked increases in apoptosis rate. These results strongly suggest that Ctrb is capable of triggering apoptosis through a mitochondrial pathway via cleavage of Bid.
Suppression of endogenous Ctrb activity attenuated TNF-α-induced apoptosis
To further demonstrate the involvement of Ctrb in the apoptotic regulation, we reduced the endogeneous Ctrb activity by its specific inhibitor TPCK or RNA interference. a. Chymotrypsin B inhibitor TPCK treatment.
RH-35 cells were treated with TNF-α (100 ng/ml), and its apoptosis was quantified by flow cytometry. (Fig 7b) . We then determined the survival of cells transfected with pSUPER-Ctrb or pSUPER-LacZ vectors under the condition of 100 ng/ml TNF-α treatment. As shown in Fig. 7c , cells transfected with pSUPER-Ctrb had a survival rate of 59.8%, significantly higher than that of cells transfected with pSUPER-LacZ vector (39.5%), suggesting that RNAi-mediated knockdown of endogenous Ctrb expression significantly decreased TNF-α-induced apoptosis. Taking the results together, Ctrb is identified as one of the executors and mediators that regulates apoptosis in RH-35 cells induced by TNF-α.
Discussion
Caspases are well known to be universal apoptotic executioners. Recently, non-caspase death effectors including calpains, granzymes, Omi/htra2, and lysosomal cathepsins have been reported to be involved in apoptosis [15, 16] . It has been strongly suggested that mild perturbation of lysosomes followed by release of entrapped enzymes can initiate apoptosis via a lysosomal-mitochondrial pathway [5] [6] [7] [8] [9] . An attractive candidate bridging the lysosomal proteases and the downstream mitochondrial membrane permeabilization (MMP) is Bid. Bid has been identified as a substrate of caspase 8, calpain, granzyme B, and cathepsins [3, 4, 6, 17] . So far, several orthodox lysosomal cathepsins have been shown to activate Bid and induce apoptosis [9, 18] . Nevertheless, this function of cathepsins remains controversial [8, 19] . It has been suggested that, besides the known papain-like cathepsins, other lysosomal proteases might exist and be involved in apoptotic regulation through Bid cleavage. In this study, we have purified a protease from rat liver lysosomes with strong Bid cleavage activity that is optimal at neutral pH. Via biochemical and mass spectrometric assays, this protease was identified as Chymotrypsin B (Ctrb), a well-known secretory protease synthesized in pancreas. We have now demonstrated for the first time that Ctrb co-localizes with lysosomes of rat hepatocytes. In view of the release of Ctrb from lysosomes during apoptosis and its pro-apoptotic property, Ctrb could be involved in the lysosomal-mitochondrial apoptotic pathway. In addition to cathepsins, which normally function at an acidic pH, Ctrb, which functions optimally at the neutral pH of cytosol, should be recognized as another class of lysosomal proteases potentially involved in the regulation of apoptosis. It is interesting to note that both RNAi studies and pretreatment of RH-35 cells with specific inhibitor of Ctrb, TPCK, could significantly but partly attenuated apoptosis induced by TNF-α. Transfection of pSUPER-Ctrb caused a marked (~70%) decrease in Ctrb mRNA levels, and resulted in a moderate (~20%) decrease in the apoptosis rate upon TNF-α treatment, comparable to that as a result of silencing cathepsins [8] . This suggests that Ctrb contributes to TNF-α-induced apoptosis in RH-35 cells. However, the relative contributions of Ctrb and other pro-apoptotic proteases to apoptosis and their mutual effects (synergetic or simply additive) deserves further investigation. The manner by which Ctrb is retained in lysosomes and is activated in vivo remains an open question. The luminal pH and redox potential within the late endolysosomal system are subtly designed to denature substrates, allowing for increased hydrolytic efficiency. These unique conditions impose stringent requirements that can be met almost exclusively by cathepsins in their mature forms. In contrast, Ctrb is incompatible with the denaturing luminal environment, with acidification leading to substantial loss of its activity [20] . We would like to suppose that lysosomal Ctrb must take on a strategy to protect from the deleterious conditions in the lysosomal lumina and sustain its potential as a neutral serine protease. Actually, in our purification procedure, we did observe lysosomal Ctrb underwent a drastic increase of Ctrb activity following in vitro incubation (see Fig. 1b ), which indicates its inactive but potentially activable status in lysosomes. Presumably, lysosome Ctrb might be stored in its premature form, chymotrypsinogen B, or alternatively, co-exist with an inhibitory factor. This form of Ctrb may then secede from lysosomes to the cytosol under either physiological or pathological conditions in intact cells. The details underlying the release and activation of Ctrb in vitro remain unknown. There is a growing body of evidence in apoptosis research that supports the participation of chymotrypsin-like serine proteases in cell death regulation [21, 22] . Most of this evidence was obtained by using specific inhibitors (mainly TPCK) [21, 23] and implicates serine proteases in various steps of the apoptotic process, such as being the intermediate linking early lysosomal rupture and MMP [24] and having a role in the postmitochondrial stage [25] , and the terminal stage of internucleosomal DNA fragmentation [26] . These versatile actions indicate variability in the abundance, localization and physiological substrates of the putative chymotrypsin-like proteases within individual apoptotic cells. However, little is known about the family members and the targets of their actions during the apoptotic process. Granzymes are serine family proteases involved in apoptosis regulation, whereas they are found exclusively in the cytoplasmic granules within cytotoxic T cells and natural killer cells, and following their secretion enter the target cell via endocytosis and induce apoptosis. In contrast, Ctrb represents the first discovered neutral serine protease that ubiquitously distributes in conventional lysosomes of various cell types, and functions intracellulary as an pro-apoptotic agent. This finding raises many questions including the regulation of Ctrb expression and activity, the trafficking mechanism responsible for its lysosomal delivery, its cellular targets and other novel roles. We anticipate that our findings will stimulate additional interest to serine protease-dependent apoptosis and will gain a deeper insight into the complex nature of apoptosis when the aforementioned questions are answered. Other lysosomal proteases are known to be multi-tasking with extralysosomal roles in the cytosol, nucleus and cell exterior during both normal cell function and pathological conditions such as cancer, inflammation and neurodegenerative disorders [27] . Thus, the interrelationship between Ctrb and the other lysosomal proteases is also interesting and deserves further study. The wide tissue expression and lysosomal localization of Ctrb suggest that it might be involved in some important physiological and/or pathological events. It is therefore possible that Ctrb performs other functions that are unrelated to induction of apoptosis. To sum up, our finding encourages a rethinking of the function of Ctrb and further study to elucidate its substrates, and could possibly change the specific function assigned to Ctrb from an intestinal digestive protease to a more important mediator in cells. 
